生长抑素类似物联合依维莫司治疗胰腺神经内分泌肿瘤的临床疗效观察

doi:10.3969/j.issn.1001-8131.2022.06.007

Abstract
Figure/Table
References
Related Citation (1)

Download: PDF (427 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the clinical efficacy of somatostatin analogists combined with everolimus in the treatment of pancreatic neuroendocrine tumors. Methods A total of 54 patients with pancreatic neuroendocrine tumor admitted to our hospital were selected and divided into observation group（n=27）and control group（n=27）according to random number table method.The control group was treated with somatostatin analogue,and the observation group was treated with somatostatin analogue combined with everolimus.The treatment effect,time to progression,recurrence rate 1-3 years after operation,serum CgA level and the incidence of related complications were compared between the two groups. Results The time to progression in the observation group was significantly longer than that in the control group,and the 1-3 years recurrence rate was significantly lower than that in the control group（P<0.05）.After 3 months of treatment,the serum CGA level in the observation group was significantly lower than that in the control group（P<0.05）.However,the incidence of adverse reactions（mainly oral inflammation）in the observation group was significantly higher than that in the control group（P<0.05）. Conclusion The clinical efficacy of somatostatin analogue combined with everolimus in the treatment of pancreatic neuroendocrine tumors is better than that of somatostatin analogue alone,which can prolong the time to progression and reduce disease recurrence in patients.However,the incidence of adverse reactions in patients taking everolimus is higher,which needs to be solved clinically.

Key words： Somatostatin analogue Everolimus Pancreatic neuroendocrine tumor

Received: 25 August 2021

PACS:

R735.9

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Chen Xiaolan
	Shang Qingling
	Li Hui

Cite this article:

Chen Xiaolan,Shang Qingling,Li Hui. Clinical Efficacy of Somatostatin Analogues Combined With Everolimus in the Treatment of Pancreatic Neuroendocrine Tumors[J]. journal1, 2022, 42(6): 17-19.

URL:

http://www.hrbyybjb.org.cn/EN/10.3969/j.issn.1001-8131.2022.06.007 OR http://www.hrbyybjb.org.cn/EN/Y2022/V42/I6/17

[1] 吴霜,肖秀丽,叶入裴,等.胃肠胰神经内分泌肿瘤的临床病理特点(附104例分析)[J].山东医药,2017,27(32):81-84.
[2] 姜雅慧,张靖宜,郭玉虹,等.182例胰腺神经内分泌肿瘤的临床病理特征和预后分析[J].中国肿瘤临床,2019,46(21):29-38.
[3] 张俊,姜毓,沈柏用.胰腺神经内分泌肿瘤的治疗[J].外科理论与实践,2019,24(3):208-211.
[4] 陈洛海,陈洁.胰腺神经内分泌肿瘤的药物治疗及其进展[J].中国实用外科杂志,2019,39(9):929-934.
[5] 周晓军,樊祥山.解读2010年消化系统肿瘤WHO分类(三)[J].临床与实验病理学杂志,2011,27(11):1153-1160.
[6] 中国胃肠胰神经内分泌肿瘤病理专家组.中国胃肠胰神经内分泌肿瘤病理学诊断共识[J].中华病理学杂志,2011,40(4):257-262.
[7] 艾森豪尔. 固体肿瘤的新反应评估标准:修订后的REIST指南(第1.1版)[J].欧洲癌症杂,2009,45(2):241-247.
[8] 吴爽,韩宇.胃肠胰神经内分泌肿瘤药物治疗进展[J].中国肿瘤临床,2018,21(8):422-426.
[9] 包旭东,卢琳,潘慧,等.功能性胰腺神经内分泌肿瘤的药物治疗进展[J].临床药物治疗杂志,2019,17(11):18-23.
[10] 陈文祺,毛威麟,韩序,等.胃肠胰神经内分泌肿瘤分子靶向治疗研究进展[J].中华消化外科杂志,2020,19(11):1224-1228.
[11] 王鑫,陈莹莹,谭煌英.生长抑素类似物对复发性Ⅰ型胃神经内分泌肿瘤的疗效[J].中日友好医院学报,2020,34(1):33-35.
[12] 乔振宇,王健,吕晓业,等.依维莫司和MK-2206联合用药协同抑制肝癌细胞增殖[J].中国药理学与毒理学杂志,2017,31(8):793-799.
[13] 吴俊,卢仁泉,郭林.血清嗜铬粒蛋白A检测在神经内分泌肿瘤中的应用价值[J].检验医学,2019,34(2):122-125.
[14] 程月鹃,白春梅.依维莫司治疗晚期神经内分泌肿瘤研究进展[J].中华医学杂志,2017,97(6):478-480.
[15] 赖鹏,胡骁轶,郭剑明.依维莫司与阿昔替尼二线治疗转移性肾细胞癌(mRCC)的临床疗效及不良反应比较[J].复旦学报(医学版),2020,47(1):41-45.
[16] 薛晨,杨建征,石光,等.mTOR抑制剂依维莫司联合内分泌治疗在老年乳腺癌中的研究进展[J].实用老年医学,2019,33(7):721-724.